Imcyse SA Alternatives & Competitors

12 companies similar to Imcyse SA — Pioneering the development of Imotopes™ to prevent, stop and potentially cure au...

Repertoire Immune Medicines

Repertoire is a biotechnology company creating a new category of immune medicines for canc...

86 Series B $189.00M

Cambridge, United States

Biotechnology Health and Wellness +1

Rocket Pharmaceuticals

Seeking gene therapy cures

222 IPO $725.80M

Cranbury, United States

Biotechnology Health Care +1

Dianthus Therapeutics, Inc.

Building a leading biotech company focused in severe autoimmune diseases.

124 Post Ipo Equity $351.50M

United States

Biopharma Biotechnology +1

Compare

Mozart Therapeutics, Inc.

Orchestrating the Immune System

36 Series A $80.00M

Seattle, United States

Biotechnology

Track all Imcyse SA competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Io Therapeutics

Io therapeutics focuses on developing drugs that target nuclear receptors in order to trea...

5 Unknown $4.64M

Adendra Therapeutics

Translating dendritic cell biology into new therapies for cancer and autoimmunity.

3 Series A $53.00M

London, United Kingdom

Biopharma Biotechnology +1

Replicate Bioscience, Inc.

The Power of RNA Amplified

22 Series A $46.00M

San Diego, United States

Biotechnology

GlycoEra AG

Advancing Glycan Mediated Therapy

30 Series B $179.00M

Wadenswil, Switzerland

Biotechnology Health Care

Granza Bio

Reprogramming Immunity for Target-Specific Medicines

7 Seed $7.64M

Biopharma Biotechnology +1

Sitryx

Harnessing the power of cell metabolism to develop groundbreaking disease-modifying therap...

48 Series A $79.00M

Oxford, United Kingdom

Biotechnology Health Care +1

Asylia Therapeutics

Innovative therapies reshaping immune responses against autoimmune, cancer, and infectious...

1 Series A $14.50M

Biotechnology Health Care +1

Fate Therapeutics Inc.

Transforming the lives of patients with autoimmune diseases and cancer.

227 Unknown $1.24B

San Diego, United States

Biotechnology Health Care +1

About Imcyse SA

Pioneering the development of Imotopes™ to prevent, stop and potentially cure autoimmune diseases

Services

Development of immunotherapies, Clinical trials for autoimmune diseases, Partnership-driven commercialization

Target Customers

Patients with autoimmune diseases, Healthcare institutions, Pharmaceutical partners, Academic researchers

Taxonomy

Autoimmune Diseases, Active Specific Immunotherapy, Imotopes™, Type 1 Diabetes, Immunotherapies, Cytolytic CD4 T-cells, Antigen-Presenting Cells, Synthetic Peptides, Biopharmaceuticals, Clinical Trials, Multiple Sclerosis, Intellectual Property, Imcyse Technology Platform, Chronic Autoimmune Diseases

Business Model

B2B, B2D

Revenue Model

Licensing

Frequently Asked Questions

Top alternatives to Imcyse SA include Repertoire Immune Medicines, Rocket Pharmaceuticals, Dianthus Therapeutics, Inc., Mozart Therapeutics, Inc., Io Therapeutics. These companies serve similar markets and are frequently compared.

Bounce Watch tracks 12 companies similar to Imcyse SA based on industry overlap, target customers, and business model.

Pioneering the development of Imotopes™ to prevent, stop and potentially cure autoimmune diseases

Don't just read about them. Follow them.

BounceWatch watches Imcyse SA and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Imcyse SA Profile Repertoire Immune Medicines Alternatives Rocket Pharmaceuticals Alternatives Dianthus Therapeutics, Inc. Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Imcyse SA on 23 Feb 2026. The 12 companies listed here were last checked between 28 Jan 2026 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.